Research Analysts Set Expectations for EW FY2024 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Research analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Edwards Lifesciences in a note issued to investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings of $2.58 per share for the year, up from their previous forecast of $2.57. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q1 2025 earnings at $0.57 EPS, Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.62 EPS, Q4 2025 earnings at $0.66 EPS, FY2025 earnings at $2.46 EPS and FY2027 earnings at $3.33 EPS.

EW has been the topic of several other reports. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Robert W. Baird lowered their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Citigroup dropped their target price on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research report on Tuesday, October 1st. Royal Bank of Canada upped their price target on shares of Edwards Lifesciences from $75.00 to $80.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Barclays dropped their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $76.85.

Edwards Lifesciences Stock Up 0.7 %

Shares of Edwards Lifesciences stock opened at $72.07 on Wednesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a market cap of $42.51 billion, a price-to-earnings ratio of 10.40, a price-to-earnings-growth ratio of 4.01 and a beta of 1.12. The company’s 50 day moving average is $68.01 and its 200 day moving average is $75.32.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the firm earned $0.59 EPS. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of EW. First Community Trust NA bought a new position in Edwards Lifesciences during the second quarter valued at $29,000. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the third quarter worth about $32,000. Avior Wealth Management LLC increased its stake in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares during the last quarter. Finally, Webster Bank N. A. purchased a new stake in Edwards Lifesciences during the second quarter valued at approximately $39,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock valued at $2,657,000 in the last three months. 1.27% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.